

What Clinicians Want To Know: Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Gastrointestinal Cancers

Select Publications

VAN CUTSEM

Ajani JA et al. **Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.** *J Clin Oncol* 2010;28(9):1547-53.

Bang YJ et al. **Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GE junction cancer (ToGA): A Phase 3, open-label, randomised controlled trial.** *Lancet* 2010;376(9742):687-97.

Bang Y et al. **Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.** *Proc ASCO* 2009; **Abstract 4556.**

Cunningham D et al. **Capecitabine and oxaliplatin for advanced esophagogastric cancer.** *N Engl J Med* 2008;358(1):36-46.

Dank M et al. **Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.** *Ann Oncol* 2008;19(8):1450-7.

Hofmann M et al. **Assessment of a HER2 scoring system for gastric cancer: Results from a validation study.** *Histopathology* 2008;52(7):797-805.

Hubbard SR. **EGF receptor inhibition: Attacks on multiple fronts.** *Cancer Cell* 2005;7(4):287-8.

Kang YK et al. **Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial.** *Ann Oncol* 2009;20(4):666-73.

Murad AM et al. **Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.** *Cancer* 1993;72(1):37-41.

Van Cutsem E et al. **Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group.** *J Clin Oncol* 2006;24(31):4991-7.

Vanhoefer U et al. **Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.** *J Clin Oncol* 2000;18(14):2648-57.

HALLER

Benson AB 3rd, Hamilton SR. **Path toward prognostication and prediction: An evolving matrix.** *J Clin Oncol* 2011;29(35):4599-601.

Benson AB et al. **American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.** *J Clin Oncol* 2004;22(16):3408-19.

Gray RG et al. **Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.** *J Clin Oncol* 2011;29(35):4611-9.

Haller DG et al. **Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS).** *Proc ASCO* 2010;Abstract 3521.

Jackson McCleary NA et al. **Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT database.** *Proc ASCO* 2009;Abstract 4010.

Kerr D et al. **A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.** *Proc ASCO* 2009;Abstract 4000.

Sargent DJ et al. **Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.** *J Clin Oncol* 2010;28(30):3219-26.

VENOOK

Abou-Alfa GK et al. **Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis.** *Gastrointest Cancer Res* 2011;4(2):40-4.

Forner A et al. **Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?** *Cancer* 2009;115(3):616-23.

Llovet JM et al. **Design and endpoints of clinical trials in hepatocellular carcinoma.** *J Natl Cancer Inst* 2008;100(10):698-711.

Llovet JM et al. **Sorafenib in advanced hepatocellular carcinoma.** *N Engl J Med* 2008;359(4):378-90.

Llovet JM et al. **Hepatocellular carcinoma.** *Lancet* 2003;362(9399):1907-17.

Llovet JM et al. **Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial.** *Lancet* 2002;359(9319):1734-9.

Miller AA et al. **Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.** *J Clin Oncol* 2009;27(11):1800-5.

Pinter M et al. **Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.** *Oncologist* 2009;14(1):70-6.

Takayasu K et al. **Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.** *Gastroenterology* 2006;131(2):461-9.

GROTHEY

Chun YS et al. **Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.** *JAMA* 2009;302(21):2338-44.

Douillard JY et al. **Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study.** *J Clin Oncol* 2010;28(31):4697-705.

Falcone A et al. **Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest.** *J Clin Oncol* 2007;25(13):1670-6.

Folprecht G et al. **Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates.** *Ann Oncol* 2005;16(8):1311-9.

Maughan TS et al. **Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial.** *Lancet* 2011;377(9783):2103-14.

Nordlinger B et al. **Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial.** *Lancet* 2008;371(9617):1007-16.

Okines A et al. **Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer — First BEAT and the randomized phase-III NO16966 trial.** *Br J Cancer* 2009;101(7):1033-8.

Saltz LB et al. **Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study.** *J Clin Oncol* 2008;26(12):2013-9.

Zorzi D et al. **Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.** *Br J Surg* 2007;94(3):274-86.

O'REILLY

Von Hoff DD et al. **Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial.** *J Clin Oncol* 2011;29(34):4548-54.

FUCHS

De Roock W et al. **Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.** *JAMA* 2010;304(16):1812-20.

Tejpar S et al. **Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.** *Proc ASCO* 2011;Abstract 3511.

Van Cutsem E et al. **Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR).** 13th ESMO World Congress on Gastrointestinal Cancer 2011;Abstract 0-0024.